Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZ Olive Immunotherapy Tolerability Trial
NCT01674595Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2012
- Primary completion
- Apr 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Alutard Avanz SQ in allergic rhinitis (AR), sponsored by ALK-Abelló. Started Sep 2012; status: completed.
02
Drugs
Alutard Avanz SQ
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01674595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01674595.